文献速递流行病学与生物统计基础与转化研究

纽约市COVID-19危重成人患者的前瞻性队列研究:流行病学、临床病程与结局

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.
PubMed 文献 · Lancet · 2020-05-19

本研究前瞻性纳入2020年3月2日至4月1日纽约两家医院收治的1150例实验室确诊COVID-19成人患者,其中257例(22%)为危重患者。截至4月28日,危重患者中39%死亡、37%仍住院,79%接受有创机械通气,中位通气时间18天。多变量Cox模型显示高龄、慢性心脏病、慢性肺病、白介素-6和D-二聚体升高与院内死亡独立相关。

要点

  • COVID-19住院患者中危重比例高(22%),有创机械通气使用率达79%。
  • 危重患者院内死亡率高(39%),需关注肺外器官功能障碍。
  • 高龄、慢性心肺疾病、IL-6和D-二聚体升高是院内死亡的独立危险因素。

核心结论

  • 纽约市COVID-19住院患者中危重疾病常见,与高频有创机械通气、肺外器官功能障碍和显著的院内死亡率相关。

研究设计与样本

  • 前瞻性观察性队列研究,在纽约北部曼哈顿两家纽约长老会医院(哥伦比亚大学欧文医学中心附属)进行。
  • 前瞻性识别2020年3月2日至4月1日收治的成人(≥18岁)实验室确诊COVID-19且危重(急性低氧性呼吸衰竭)患者,收集临床、生物标志物和治疗数据。
  • 主要结局为院内死亡率;次要结局包括有创机械通气的频率和持续时间、血管加压药使用和肾脏替代治疗的频率、入院后临床恶化时间。
  • 采用Cox比例风险回归模型分析临床危险因素、生物标志物与院内死亡率的关系;随访时间右删失于2020年4月28日,确保每例患者至少观察28天。

主要发现

  • 2020年3月2日至4月1日,两家医院共收治1150例实验室确诊COVID-19成人,其中257例(22%)为危重患者。
  • 患者中位年龄62岁(IQR 51-72),171例(67%)为男性;212例(82%)有至少一种慢性病,最常见为高血压(162例[63%])和糖尿病(92例[36%]);119例(46%)有肥胖。
  • 截至2020年4月28日,101例(39%)死亡,94例(37%)仍住院。
  • 203例(79%)接受有创机械通气,中位通气时间18天(IQR 9-28);170例(66%)使用血管加压药,79例(31%)接受肾脏替代治疗;中位入院至临床恶化时间为3天(IQR 1-6)。

临床怎么用

  • 对COVID-19住院患者应早期识别危重风险,高龄、慢性心肺疾病及IL-6、D-二聚体升高者需密切监测。
  • 危重患者常需有创机械通气和肺外器官支持,应提前规划重症资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Over 40 000 patients with COVID-19 have been hospitalised in New York City (NY, USA) as of April 28, 2020. Data on the epidemiology, clinical course, and outcomes of critically ill patients with COVID-19 in this setting are needed. METHODS: This prospective observational cohort study took place at two NewYork-Presbyterian hospitals affiliated with Columbia University Irving Medical Center in northern Manhattan. We prospectively identified adult patients (aged ≥18 years) admitted to both hospitals from March 2 to April 1, 2020, who were diagnosed with laboratory-confirmed COVID-19 and were critically ill with acute hypoxaemic respiratory failure, and collected clinical, biomarker, and treatment data. The primary outcome was the rate of in-hospital death. Secondary outcomes included frequency and duration of invasive mechanical ventilation, frequency of vasopressor use and renal replacement therapy, and time to in-hospital clinical deterioration following admission. The relation between clinical risk factors, biomarkers, and in-hospital mortality was modelled using Cox proportional hazards regression. Follow-up time was right-censored on April 28, 2020 so that each patient had at least 28 days of observation. FINDINGS: Between March 2 and April 1, 2020, 1150 adults were admitted to both hospitals with laboratory-confirmed COVID-19, of which 257 (22%) were critically ill. The median age of patients was 62 years (IQR 51-72), 171 (67%) were men. 212 (82%) patients had at least one chronic illness, the most common of which were hypertension (162 [63%]) and diabetes (92 [36%]). 119 (46%) patients had obesity. As of April 28, 2020, 101 (39%) patients had died and 94 (37%) remained hospitalised. 203 (79%) patients received invasive mechanical ventilation for a median of 18 days (IQR 9-28), 170 (66%) of 257 patients received vasopressors and 79 (31%) received renal replacement therapy. The median time to in-hospital deterioration was 3 days (IQR 1-6). In the multivariable Cox model, older age (adjusted hazard ratio [aHR] 1·31 [1·09-1·57] per 10-year increase), chronic cardiac disease (aHR 1·76 [1·08-2·86]), chronic pulmonary disease (aHR 2·94 [1·48-5·84]), higher concentrations of interleukin-6 (aHR 1·11 [95%CI 1·02-1·20] per decile increase), and higher concentrations of D-dimer (aHR 1·10 [1·01-1·19] per decile increase) were independently associated with in-hospital mortality. INTERPRETATION: Critical illness among patients hospitalised with COVID-19 in New York City is common and associated with a high frequency of invasive mechanical ventilation, extrapulmonary organ dysfunction, and substantial in-hospital mortality. FUNDING: National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences, National Institutes of Health, and the Columbia University Irving Institute for Clinical and Translational Research.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020. PMID: 32442528. doi:10.1016/S0140-6736(20)31189-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。